Related Experiment Video

Updated: Dec 28, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.1K

[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]

    Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases
    |February 21, 2020
    PubMed

    Insights

    Chloroquine phosphate may improve treatment success and shorten hospital stays for patients with novel coronavirus pneumonia (COVID-19). This expert consensus recommends a specific dosage for mild, moderate, and severe cases.

    Area of Science:

    • Virology
    • Infectious Diseases
    • Pharmacology

    Context:

    • The COVID-19 pandemic emerged in late 2019, rapidly spreading globally and creating a severe epidemic prevention challenge.
    • No specific antiviral treatment was available for COVID-19 at the time of the study.
    • Chloroquine phosphate demonstrated broad-spectrum antiviral activity, including against coronaviruses, in prior research.

    Purpose:

    • To evaluate the efficacy of chloroquine phosphate in treating patients with novel coronavirus pneumonia (COVID-19).
    • To provide expert recommendations for the clinical application of chloroquine phosphate in COVID-19 treatment.

    Summary:

    • A multicenter expert consensus was developed to guide chloroquine use in COVID-19 patients.
    • The consensus recommends chloroquine phosphate (500mg twice daily for 10 days) for mild, moderate, and severe COVID-19 cases without contraindications.
    • Findings suggest chloroquine may improve treatment success rates, reduce hospital stays, and enhance patient outcomes.

    Impact:

    • Provides evidence-based guidance for clinicians managing COVID-19 patients.
    • Contributes to the understanding of potential therapeutic agents for novel coronavirus infections.
    • Aims to optimize patient outcomes during the COVID-19 pandemic.

    Keywords:
    ChloroquineNovel coronavirus pneumonia

    More Related Videos

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

    Published on: January 2, 2017

    15.1K
    Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds07:14

    Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

    Published on: July 11, 2025

    468

    Related Concept Videos

    Antimicrobial Effectiveness01:28

    Antimicrobial Effectiveness

    The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
    850
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    685
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    174
    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    459
    Anticholinesterase Agents: Poisoning and Treatment01:26

    Anticholinesterase Agents: Poisoning and Treatment

    Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
    Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
    1.4K
    Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

    Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

    Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
    222